Premium
Can we prevent Alzheimer's disease? Secondary “prevention” trials in Alzheimer's disease
Author(s) -
Carrillo Maria C.,
Brashear H. Robert,
Logovinsky Veronika,
Ryan J. Michael,
Feldman Howard H.,
Siemers Eric R.,
Abushakra Susan,
Hartley Dean M.,
Petersen Ronald C.,
Khachaturian Ara S.,
Sperling Reisa A.
Publication year - 2013
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2012.12.004
Subject(s) - disease , dementia , secondary prevention , alzheimer's disease , medicine , clinical trial , primary prevention , gerontology , psychology , pathology
Current research including the basic biology of Alzheimer's disease (AD) provides a foundation to explore whether our current state of knowledge is sufficient to initiate prevention studies and allow us to believe prevention of AD is possible. Current research and recently revised criteria for the diagnosis of AD by the National Institutes on Aging and the Alzheimer's Association suggest a continuum of disease from preclinical asymptomatic to symptomatic Alzheimer's dementia. In light of these revised criteria, the possibility of secondary prevention and even primary prevention is under discussion. The Alzheimer's Association Research Roundtable convened a meeting to discuss the rationale and feasibility of conducting secondary prevention trials in AD.